Anti-angiogenic therapy for ovarian cancer

Angiogenesis is a known hallmark in cancer and plays a crucial role in ovarian cancer carcinogenesis and invasion. Anti- angiogenic agents are active in ovarian cancer treatment either as monotherapy or combined with chemotherapy, immunotherapy or poly ADP ribose polymerase (PARP) inhibitors. We rev...

Descripción completa

Detalles Bibliográficos
Autores principales: García García, Yolanda, Marín Alcalá, Maria, Martínez Vila, Clara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573465/
https://www.ncbi.nlm.nih.gov/pubmed/33240446
http://dx.doi.org/10.1016/j.ejcsup.2020.02.003
_version_ 1783597445605752832
author García García, Yolanda
Marín Alcalá, Maria
Martínez Vila, Clara
author_facet García García, Yolanda
Marín Alcalá, Maria
Martínez Vila, Clara
author_sort García García, Yolanda
collection PubMed
description Angiogenesis is a known hallmark in cancer and plays a crucial role in ovarian cancer carcinogenesis and invasion. Anti- angiogenic agents are active in ovarian cancer treatment either as monotherapy or combined with chemotherapy, immunotherapy or poly ADP ribose polymerase (PARP) inhibitors. We review the mechanism of action, clinical activity and safety profile of the most important drugs either in the actual treatment or in current evaluation in the ovarian cancer treatment scenario (neoadjuvant, first line and relapse).
format Online
Article
Text
id pubmed-7573465
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-75734652020-11-24 Anti-angiogenic therapy for ovarian cancer García García, Yolanda Marín Alcalá, Maria Martínez Vila, Clara EJC Suppl Article Angiogenesis is a known hallmark in cancer and plays a crucial role in ovarian cancer carcinogenesis and invasion. Anti- angiogenic agents are active in ovarian cancer treatment either as monotherapy or combined with chemotherapy, immunotherapy or poly ADP ribose polymerase (PARP) inhibitors. We review the mechanism of action, clinical activity and safety profile of the most important drugs either in the actual treatment or in current evaluation in the ovarian cancer treatment scenario (neoadjuvant, first line and relapse). Elsevier 2020-08-22 /pmc/articles/PMC7573465/ /pubmed/33240446 http://dx.doi.org/10.1016/j.ejcsup.2020.02.003 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
García García, Yolanda
Marín Alcalá, Maria
Martínez Vila, Clara
Anti-angiogenic therapy for ovarian cancer
title Anti-angiogenic therapy for ovarian cancer
title_full Anti-angiogenic therapy for ovarian cancer
title_fullStr Anti-angiogenic therapy for ovarian cancer
title_full_unstemmed Anti-angiogenic therapy for ovarian cancer
title_short Anti-angiogenic therapy for ovarian cancer
title_sort anti-angiogenic therapy for ovarian cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573465/
https://www.ncbi.nlm.nih.gov/pubmed/33240446
http://dx.doi.org/10.1016/j.ejcsup.2020.02.003
work_keys_str_mv AT garciagarciayolanda antiangiogenictherapyforovariancancer
AT marinalcalamaria antiangiogenictherapyforovariancancer
AT martinezvilaclara antiangiogenictherapyforovariancancer

Ejemplares similares